-transparent.png){kind=logo}
OBJECTIVE To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. METHODS Case note review. Main outcome measure was recurrence of uveitis. RESULTS All patients remained free of recurrence with stable visual acuities. CONCLUSIONS Adalimumab appears to maintain disease remission in Behçet's disease.
Related Publications
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
July 1994,
American journal of ophthalmology,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
April 2021,
International immunopharmacology,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
July 2019,
Journal of ophthalmic inflammation and infection,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
July 2001,
Lancet (London, England),
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
June 2019,
Pediatric rheumatology online journal,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
December 2018,
BMJ case reports,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
June 2014,
Rheumatology international,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
May 2005,
The British journal of ophthalmology,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
January 2003,
Advances in experimental medicine and biology,
B Mushtaq, and
T Saeed, and
R D Situnayake, and
P I Murray
December 2017,
Postgraduate medical journal,
